Get the App

Back Stocks profile

Stock analysis tool for investors

Aurobindo Pharma Ltd.

NSE: AUROPHARMA | BSE:524804

₹1115.30 -20.80 (-1.83%) 1D

Pharmaceuticals & Biotechnology

Buy Sell
View detailed Technical chart

Open an Account with Bigul in 5 minutes

Performance

Today’s low

1112.20

Today’s High

1155.00

52W low

581.20

52W High

1177.10

Open Price

1136.00

Prev. Close

1011.3000

Volume

1467778.00

Value

1637012803.40

Fundamentals

Market Cap Cr

65349.70

Price to Earnings

23.60

Price to Book Value

2.40

Dividend Yield

0.40

PE to Growth

0.60

Op Revenue TTM Cr

27894.68

Net Profit TTM Cr

2770.49

Cash From Operating Activity Cr

2386.75

Return on Equity %

7.18

EMA & SMA

Bullish Moving Averages

9

Bearish Moving Averages

7

5Day EMA

1131.7

10Day EMA

1131

12Day EMA

1129.1

20Day EMA

1120

26Day EMA

1113.5

50Day EMA

1094.7

100Day EMA

1060.1

200Day EMA

975.6

5Day SMA

1138.1

10Day SMA

1138.7

20Day SMA

1118.4

30Day SMA

1110.6

50Day SMA

1081.7

100Day SMA

1079.4

150Day SMA

1034.1

200Day SMA

987.3

DELIVERY AND VOLUME

DAILY AVG. DELIVERY VOLUME %

09 May, 2024

44.3

Week

43.2

Month

52.6

LEGEND

Positive Indicator

Neutral Indicator

Negative Indicator

RESISTANCE AND SUPPORT

1127.48

PIVOT

First Resistance

1142.82

Second Resistance

1170.33

Third Resistance

1185.67

First Support

1099.97

Second Support

1084.63

Third Support

1057.12

Relative Strength Index

50.67

Money Flow Index

63.39

MACD

15.56

MACD Signal

17.04

Average True Range

33.55

Average Directional Index

19.31

Rate of Change (21)

-0.75

Rate of Change (125)

27.64

Commodity Channel Index

25.6

Williams %R

-59.6

BETA

1 Month

0.38

3 Month

0.73

1 Year

0.57

3 Year

0.2

PRICE CHANGE ANALYSIS

↓ -3.31%

1 Week

Low

High

1097.1

1172

↓ -0.44%

1 Month

Low

High

1069.3

1175.8

↑ 11.24%

3 Months

Low

High

958.5

1175.8

↑ 19.09%

6 Months

Low

High

929.3

1177.1

↑ 80.19%

1 Year

Low

High

581.25

1177.1

Indicator Dec 2023 Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022 Dec 2021 Sep 2021 Jun 2021 Graph
Total Qtr Revenue cr 3023.16 2735.84 2485.70 3835.61 3510.99 3081.52 2825.63 3300.54 2754.34 2965.55 2920.78
Operating Expenses Qtr 2210.34 2123.58 1968.44 2855.61 2959.04 2729.76 2544.66 2380.20 2407.14 2543.45 2466.02
Operating Profit Qtr 481.69 545.18 422.38 691.83 473.22 295.90 242.26 506.97 215.91 339.73 427.73
EBIDT Qtr Cr 812.82 648.35 517.26 980.00 551.95 351.76 280.97 845.63 347.20 422.10 454.76
Depreciation Qtr 64.35 65.79 59.63 115.00 108.50 108.80 103.05 101.22 101.20 98.18 114.65
Net Profit Qtr 623.78 415.74 335.95 644.80 298.82 164.63 122.16 802.16 239.81 197.68 215.07
Basic EPS Qtr 10.65 7.10 5.73 11.00 5.10 2.81 2.08 13.69 4.09 3.37 3.67
Indicator Mar 2023 Mar 2022 Mar 2021 Mar 2020 Mar 2019 Graph
Total Revenue Annual 13226.04 11958.13 16413.54 13669.85 12457.11
Operating Expenses Annual Cr 11061.36 9813.74 11703.85 10580.73 9848.60
Operating Profit Annual 1730.92 1473.40 4119.83 2685.75 2409.29
Operating Profit Margin Annual % 13.09 12.32 25.10 19.65 19.34
Total Expenses Annual Cr 11611.69 10245.94 12220.53 11292.15 10492.49
EBIDT Annual Cr 2164.68 2144.39 4709.69 3089.12 2608.51
EBIDT Annual margin % 16.37 17.93 28.69 22.60 20.94
Depreciation 435.35 415.26 488.00 470.48 413.03
PAT Before ExtraOrdinary Items Annual Cr 1230.41 1454.71 3112.91 1872.74 1529.73
Net Profit Annual 1230.41 1454.71 3112.91 1872.74 1529.73
Basic EPS Annual 21.00 24.83 53.13 31.96 26.11
Indicator Mar 2023 Mar 2022 Mar 2021 Mar 2020 Mar 2019 Graph
Total ShareHolders Funds Annual 17914.17 17117.34 15924.61 13025.56 11350.62
Minority Interest Liability Annual Cr - - - - -
Total Non Current Liabilities Annual Cr 346.13 302.64 507.80 149.11 53.64
Total Current Liabilities Annual Cr 6673.35 4180.97 6756.58 6359.90 6736.46
Total Capital Plus Liabilities Annual Cr 24933.65 21600.95 23188.99 19534.57 18140.72
Fixed Assets Annual 3926.59 3810.98 5206.96 5091.31 4938.71
Total Non Current Assets Annual 15210.01 11765.84 10811.13 8286.48 7732.38
Total Current Assets Annual 9723.64 9835.11 12377.86 11248.09 10408.34
Total Assets Annual 24933.65 21600.95 23188.99 19534.57 18140.72
Contingent Liabilities plus Commitments Annual Cr 596.69 277.61 1337.36 2174.36 2736.18
Indicator Mar 2023 Mar 2022 Mar 2021 Mar 2020 Mar 2019 Graph
Cash from Operating Activity Annual 1821.16 3726.71 2994.41 2161.73 529.89
Cash from Investing Activity Annual -3459.68 -1613.51 -2648.73 -921.57 -1297.36
Cash from Financing Annual Activity 1719.48 -2447.54 -27.94 -1252.39 599.40
Net Cash Flow Annual 80.96 -334.34 317.74 -12.23 -168.07
Indicator Mar 2023 Mar 2022 Mar 2021 Mar 2020 Mar 2019 Graph
Book Value Per Share Annual 305.75 292.15 271.80 222.32 193.73
ROE Annual % 6.86 8.49 19.54 14.37 13.47
ROCE Annual % 9.47 9.92 25.69 19.87 19.25
Total Debt to Total Equity Annual 0.23 0.11 0.25 0.29 0.40
EBDIT Annual Margin % 16.92 18.99 29.76 23.28 21.28
Indicator Dec 2023 Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022 Dec 2021 Sep 2021 Jun 2021 Graph
Total Qtr Revenue cr 7514.30 7406.40 6966.85 6607.87 6499.78 5796.56 6276.54 5858.25 6067.21 6038.50 5783.29
Operating Expenses Qtr 5750.47 5845.98 5699.15 5470.78 5452.72 4948.58 5299.44 4834.97 4985.95 4755.20 4464.01
Operating Profit Qtr 1601.31 1373.44 1151.37 1002.18 954.41 790.79 936.48 974.40 1016.27 1186.72 1237.97
EBIDT Qtr Cr 1763.83 1560.42 1197.95 1137.09 1047.06 847.98 977.10 860.52 1116.05 1283.30 1319.28
Depreciation Qtr 423.27 417.50 326.56 345.57 321.40 298.10 279.51 253.57 299.05 294.21 279.69
Net Profit Qtr 936.29 757.18 570.75 506.27 491.26 409.45 520.54 576.46 604.73 696.99 769.97
Basic EPS Qtr 16.04 12.83 9.74 8.64 8.38 6.99 8.88 9.84 10.32 11.89 13.14
Indicator Mar 2023 Mar 2022 Mar 2021 Mar 2020 Mar 2019 Graph
Total Revenue Annual 25145.97 23775.84 25155.47 23290.38 19718.87
Operating Expenses Annual Cr 21136.74 19068.72 19441.22 18234.20 15611.61
Operating Profit Annual 3718.64 4386.77 5333.40 4864.31 3951.94
Operating Profit Margin Annual % 14.79 18.45 21.20 20.89 20.04
Total Expenses Annual Cr 22521.80 20243.88 20571.10 19506.04 16542.16
EBIDT Annual Cr 4009.23 4707.12 5714.25 5056.18 4107.26
EBIDT Annual margin % 15.94 19.80 22.72 21.71 20.83
Depreciation 1244.58 1126.52 1055.39 966.71 667.95
PAT Before ExtraOrdinary Items Annual Cr 1939.32 2678.36 5389.18 2844.69 2361.80
Net Profit Annual 1927.50 2648.15 5334.84 2830.97 2364.73
Basic EPS Annual 32.90 45.19 91.05 48.32 40.36
Indicator Mar 2023 Mar 2022 Mar 2021 Mar 2020 Mar 2019 Graph
Total ShareHolders Funds Annual 26839.85 24575.98 21929.87 16810.38 13890.78
Minority Interest Liability Annual Cr 12.00 -1.93 -0.88 0.14 1.59
Total Non Current Liabilities Annual Cr 1544.36 1191.69 1259.85 729.08 541.42
Total Current Liabilities Annual Cr 11493.78 8155.98 10665.15 11386.75 12020.57
Total Capital Plus Liabilities Annual Cr 39889.99 33921.72 33853.99 28926.35 26454.36
Fixed Assets Annual 15817.63 13803.87 12006.21 10466.47 9310.80
Total Non Current Assets Annual 18344.32 15799.03 14030.48 12513.85 11122.06
Total Current Assets Annual 21545.67 18122.69 19823.51 16412.50 15332.30
Total Assets Annual 39889.99 33921.72 33853.99 28926.35 26454.36
Contingent Liabilities plus Commitments Annual Cr 1813.21 1145.45 1083.17 659.39 688.84
Indicator Mar 2023 Mar 2022 Mar 2021 Mar 2020 Mar 2019 Graph
Cash from Operating Activity Annual 2386.75 5016.48 3328.92 4381.28 1650.97
Cash from Investing Activity Annual -3977.75 -3211.56 598.69 -1567.64 -2902.59
Cash from Financing Annual Activity 1814.41 -2969.27 -1364.81 -1947.18 1919.06
Net Cash Flow Annual 223.41 -1164.35 2562.80 866.46 667.44
Indicator Mar 2023 Mar 2022 Mar 2021 Mar 2020 Mar 2019 Graph
Book Value Per Share Annual 458.30 419.42 374.28 286.92 237.11
ROE Annual % 7.18 10.77 24.32 16.84 17.02
ROCE Annual % 9.73 13.89 20.09 23.31 23.82
Total Debt to Total Equity Annual 0.18 0.10 0.23 0.32 0.49
EBDIT Annual Margin % 16.13 20.06 23.06 21.88 20.99
Name Holding Percent Holding Id Pledged % Locked %
HDFC MUTUAL FUND 3.78 73809846 - -
ICICI PRUDENTIAL MUTUAL FUND 3.6 73809847 - -
Name Holding Percent Holding Id Pledged % Locked %
K NITYANANDA REDDY 4.33 73809827 42.98 0
KIRTHI REDDY KAMBAM 3.49 73809828 17.36 0
M SIVAKUMARAN 2.47 73809829 0 0
KAMBAM SPOORTHI 1.19 73809830 5.71 0
RPR SONS ADVISORS PRIVATE LIMITED, MRS.P.SUNEELA RANI (JOINTLY HOLDING) 33.51 73809838 23.81 0
AXIS CLINICALS LIMITED, TRIDENT CHEMPHAR LIMITED, RPR SONS ADVISORS PVT.LTD. (JOINTLY HOLDING) 2.85 73809839 0 0
VENKATA RAMPRASAD REDDY PENAKA 3.07 73809843 0 0
Name Holding Percent Holding Id
HDFC MUTUAL FUND 3.78 73809846
ICICI PRUDENTIAL MUTUAL FUND 3.6 73809847
MIRAE ASSET LARGE CAP FUND 2.84 73809848
QUANT MUTUAL FUND 2.54 73809849
LIFE INSURANCE CORPORATION OF INDIA 3.38 73809851
Name Holding Percent Holding Id
Ex-Date Dividend Amount Dividend Type Record Date Instrument Type
Feb 20, 2024 1.5 INTERIM Feb 20, 2024 Equity Share
Nov 20, 2023 3 INTERIM Nov 20, 2023 Equity Share
Feb 17, 2023 3 INTERIM Feb 17, 2023 Equity Share
Jun 06, 2022 4.5 INTERIM Jun 07, 2022 Equity Share
Feb 18, 2022 1.5 INTERIM Feb 21, 2022 Equity Share
Nov 17, 2021 1.5 INTERIM Nov 18, 2021 Equity Share
Aug 27, 2021 1.5 INTERIM Aug 30, 2021 Equity Share
Feb 22, 2021 1.5 INTERIM Feb 23, 2021 Equity Share
Nov 23, 2020 1.25 INTERIM Nov 24, 2020 Equity Share
Aug 21, 2020 1.25 INTERIM - Equity Share
Feb 17, 2020 1.75 INTERIM Feb 18, 2020 Equity Share
Nov 21, 2019 1.25 INTERIM Nov 23, 2019 Equity Share
Feb 15, 2019 1.25 INTERIM Feb 19, 2019 Equity Share
Nov 20, 2018 1.25 INTERIM Nov 22, 2018 Equity Share
Feb 20, 2018 1 INTERIM Feb 21, 2018 Equity Share
Nov 21, 2017 1.5 INTERIM Nov 22, 2017 Equity Share
Jun 08, 2017 1.25 INTERIM Jun 09, 2017 Equity Share
Nov 24, 2016 1.25 INTERIM Nov 25, 2016 Equity Share
Jun 09, 2016 0.7 INTERIM Jun 10, 2016 Equity Share
Feb 18, 2016 0.7 INTERIM Feb 22, 2016 Equity Share
Nov 19, 2015 0.6 INTERIM Nov 20, 2015 Equity Share
Aug 21, 2015 0.5 INTERIM - Equity Share
Jun 08, 2015 1 INTERIM Jun 09, 2015 Equity Share
Feb 16, 2015 2 INTERIM Feb 18, 2015 Equity Share
Aug 13, 2014 1.5 INTERIM - Equity Share
Jun 11, 2014 1.75 INTERIM Jun 12, 2014 Equity Share
Nov 19, 2013 1.25 INTERIM Nov 20, 2013 Equity Share
Jul 30, 2013 0.5 FINAL - Equity Share
Feb 18, 2013 1 INTERIM Feb 20, 2013 Equity Share
Jul 30, 2012 1 FINAL - Equity Share
Jul 20, 2011 1 FINAL - Equity Share
Nov 11, 2010 5 INTERIM Nov 12, 2010 Equity Share
Sep 13, 2010 2 FINAL - Equity Share
Feb 05, 2010 3 INTERIM Feb 08, 2010 Equity Share
Dec 16, 2009 1.5 FINAL - Equity Share
Feb 05, 2009 3 INTERIM Feb 06, 2009 Equity Share
Aug 11, 2008 3.25 FINAL - Equity Share
Sep 14, 2007 2.5 FINAL - Equity Share
Sep 08, 2006 1.5 FINAL - Equity Share
Sep 20, 2005 0.5 FINAL - Equity Share
Jul 22, 2004 2.25 FINAL - Equity Share
Sep 08, 2003 3.5 FINAL - Equity Share
Sep 19, 2002 3 FINAL - Equity Share
Sep 12, 2001 - FINAL - Equity Share
May 10, 2000 - INTERIM May 25, 2000 Equity Share
Ex-Date Split Ratio Record Date
Feb 10, 2011 5:1 2011-02-11
Oct 23, 2003 10:5 2003-10-31
Ex-Date Purpose Notes
Feb 10, 2024 Quarterly Results & Interim Dividend -
Nov 09, 2023 Quarterly Results & Interim Dividend -
Aug 12, 2023 Quarterly Results -
May 27, 2023 Audited Results -
Feb 09, 2023 Quarterly Results & Interim Dividend -
Nov 12, 2022 Quarterly Results -
Aug 11, 2022 Quarterly Results -
May 30, 2022 Audited Results & 4th Interim Dividend -
Feb 09, 2022 Quarterly Results & 3rd Interim Dividend -
Nov 08, 2021 Quarterly Results & 2nd Interim Dividend -
Aug 12, 2021 Quarterly Results & Interim Dividend -
May 31, 2021 Audited Results -
Feb 10, 2021 Quarterly Results & Interim Dividend -
Nov 11, 2020 Quarterly Results & Interim Dividend -
Aug 12, 2020 Quarterly Results & Interim Dividend -
Jun 03, 2020 Audited Results -
Feb 06, 2020 Quarterly Results & Interim Dividend -
Nov 12, 2019 Quarterly Results & Interim Dividend -
Aug 07, 2019 Quarterly Results -
May 28, 2019 Audited Results -
Feb 07, 2019 Quarterly Results & 2nd Interim Dividend -
Nov 12, 2018 Quarterly Results & Interim Dividend -
Aug 09, 2018 Unaudited Financial Results -
May 28, 2018 Audited Results -
Feb 07, 2018 Quarterly Results & 2nd Interim Dividend -
Nov 09, 2017 Quarterly Results & Interim Dividend -
Aug 09, 2017 Quarterly Results -
May 29, 2017 Audited Results & Dividend -
Feb 09, 2017 Quarterly Results -
Nov 14, 2016 Quarterly Results & Interim Dividend -
Aug 23, 2016 Quarterly Results -
May 30, 2016 Audited Results & Dividend Appointed Mr. B. Adi Reddy as the Company Secretary & Compliance Officer of the Company with effect from June 01, 2016.
Feb 09, 2016 Quarterly Results & 3rd Interim Dividend -
Nov 06, 2015 Raising of Funds Raising of funds through issue of securities.
Aug 12, 2015 Quarterly Results & Interim Dividend -
May 28, 2015 Audited Results & Dividend To considered and recommended for issue of ONE bonus equity share for every ONE equity share held as on a Record Date to be determined.
Feb 04, 2015 Quarterly Results & 2nd Interim Dividend -
Nov 25, 2014 To consider raising of funds Inter alia, consider raising of funds through issue of securities.
Nov 06, 2014 Quarterly Results -
Aug 07, 2014 Interim Dividend -
May 30, 2014 Audited Results & Dividend Final Dividend & Second Interim Dividend
Feb 06, 2014 Quarterly Results -
Nov 07, 2013 Quarterly Results & Interim Dividend -
Aug 09, 2013 Quarterly Results -
May 30, 2013 Audited Results & Final Dividend -
Feb 07, 2013 Quarterly Results & Interim Dividend -
Nov 09, 2012 Quarterly Results -
Aug 07, 2012 Quarterly Results -
May 29, 2012 Audited Results & Dividend -
Feb 13, 2012 Quarterly Results (Revised)
Jan 18, 2012 Appointment of Additional Director The Board has appointed Dr. C Channa Reddy as an Additional Director of the Company, He will function as a Non Executive, Independent Director of the Company.
Nov 08, 2011 Quarterly Results -
Aug 06, 2011 Quarterly Results -
May 09, 2011 Audited Results & Final Dividend -
Feb 05, 2011 Quarterly Results -
Nov 03, 2010 Interim Dividend & Stock split The Board has approved the sub-division of Equity Shares of the face value of Rs. 5/- each in the Company into Equity Shares of the face value of Re. 1/- each.
Aug 05, 2010 Quarterly Results -
May 29, 2010 Audited Results & Final Dividend -
Jan 30, 2010 Quarterly Results & Interim Dividend The Board has approved payment of an Interim Dividend @ 60% i.e. Rs. 3/- per Equity Share of Rs. 5/- each to the members of the Company for the Current Financial Year 2009-2010.
Nov 12, 2009 Audited Results, Dividend & Others To consider the draft of Scheme of Amalgamation for the Merger of Trident Life Sciences Ltd being WoS of the Co., with itself & all the assets & liabilities of Trident shall be transfered.
Oct 30, 2009 Quarterly Results -
Aug 14, 2009 Acquisition of Stake The Board has approved the proposal to acquire 100% stake of Trident Life Sciences Ltd, ("TLSL") subject to suitable agreements being executed between the parties for the same.
Jul 31, 2009 Quarterly Results -
Apr 30, 2009 Quarterly Results -
Mar 31, 2009 Scheme of Arrangement To approve the SoA, which provides the followings 1. Utilization of the Capital Redemption Reserve Account of Rs 90.0 million outstanding as on March 31, 2008 & 2. The gains arising on the buyback.
Jan 30, 2009 Quarterly Results & Interim Dividend -
Oct 31, 2008 Quarterly Results -
Jul 30, 2008 Quarterly Results -
Jun 18, 2008 Audited Results & Dividend -
Jan 30, 2008 Quarterly Results -
Oct 31, 2007 Quarterly Results -
Jul 31, 2007 Quarterly Results -
Jun 30, 2007 Audited Results & Dividend -
Jan 31, 2007 Quarterly Results -
Dec 15, 2006 Merger & ESOP Inter alia, to consider the proposal for merger of APL Life Sciences Ltd & Senor Organics Pvt Ltd, the wholly owned subsidiary Companies of the Company, with itself.
Nov 14, 2006 To acquire M/s. Senor Organics To acquire M/s. Senor Organics Pvt Ltd, a profit making, small size pharma Company based at Hyderabad.
Oct 30, 2006 Quarterly Results -
Jul 31, 2006 Quarterly Results -
Jun 27, 2006 Accounts & Dividend -
Apr 01, 2006 To consider issue of FCCBs To consider a proposal for issue of Foreign Currency Convertible Bonds (FCCBs) or other equity or equity linked securities in the overseas markets.
Oct 31, 2005 Quarterly Results -
Jul 30, 2005 Quarterly Results -
Jun 30, 2005 Accounts, Dividend & Others To consider a proposal for issue of Foreign Currency Convertible Bonds or such other similar securities in the Overseas markets.
Jan 15, 2005 Quarterly Results -
Oct 29, 2004 Quarterly Results -
Jul 31, 2004 Quarterly Results -
Jun 02, 2004 Dividend & Accounts -
Feb 18, 2004 Others To consider the allotment of equity shares of Rs 5/- each of the company to Merlion India Fund Ltd & also to appoint the nominee of Merlion on the Board of Directors of the company
Jan 31, 2004 Quarterly Results -
Nov 29, 2003 Others To issue further shares of the company on private placement/preferential allotment basis.
Oct 31, 2003 Quarterly Results -
Aug 09, 2003 Sub Division of Equity shares -
Jul 31, 2003 Quarterly Results -
Jun 30, 2003 Accounts & Dividend -
Jan 31, 2003 Quarterly Results -
Nov 15, 2002 Others Amalgamation of Ranit Pharma Ltd. and Calac Pvt. Ltd. with the company
Oct 31, 2002 Quarterly Results & Half Yearly Results -
Sep 27, 2002 Others Issue of equity shares on conversion of share warrants which were issued to promoters/directors and Templeton STrategic Emerging Markets Fund LDC
Jun 30, 2002 Accounts & Dividend -
Apr 14, 2002 Others Allotment of 10,00,000 equity shares & 10,00,000 Warrants to Templeton Emerging Markets Funds LDC.
Mar 27, 2002 Others To allot further equity shares/warrants to the promoters to the extent of receipt of subscriptions from them pursuant to the Special Resolution passed in the EGM held on 15-1-2002.
Mar 11, 2002 Revocation of Interim Dividend To consider the Revocation of Interim Dividend declared for the financial year 2001-2002.
Mar 08, 2002 Interim Dividend -
Jan 31, 2002 Quarterly Results -
Dec 14, 2001 Private Placement To issue further shares, convertible debentures or share warrants or such other instruments as the Board think fit, on private placement basis. (Revised)
Oct 31, 2001 Quarterly Results -
Jul 31, 2001 Quarterly Results -
Jun 29, 2001 Accounts & Dividend -
Jan 31, 2001 Quarterly Results -
Oct 31, 2000 Amalgamation & Quarterly Results amalgamation of Sri Chakra Remedies Ltd. with the company and Quarterly Results
Aug 28, 2000 Preferential Allotment & Right Issue of Eq. Shares -
Jul 31, 2000 Quarterly Results -
May 27, 2000 Accounts -
Mar 27, 2000 Interim dividend -
Jan 22, 2000 Quarterly Results & Bonus issue -
Oct 30, 1999 Quarterly Results -
Jul 21, 1999 Quarterly Results -
May 15, 1999 Accounts, Dividend -
Jan 30, 1999 Quarterly Results -
Oct 27, 1998 Quarterly Results -
Dec 26, 1997 Private Placement -
Nov 15, 1997 Half Yearly Results -
Ex-Date Bonus Ratio Record Date
Jul 20, 2015 1:1 2015-07-21
Mar 07, 2000 1:1 2000-04-01
Bigul
07 May 2024

AUROBINDO PHARMA LTD. - 524804 - Shareholder Meeting / Postal Ballot-Scrutinizer"s Report

 Submission of Scrutinizer''s Report on the Postal Ballot voting results for appointment of Mr. M. R. Kumar as an Independent Director of the Company.
Bigul
06 May 2024

AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Scheme of Arrangement

 Submission of Order of NCLT approving the Scheme of Amalgamation of Mviyes Pharma Ventures Private Limited and Auronext Pharma Private Limited, wholly owned subsidiaries of the Company, with the Company.
Bigul
03 May 2024

AUROBINDO PHARMA LTD. - 524804 - Completion Of US FDA Inspection At Unit II Of Eugia Pharma Specialities Ltd., A Wholly Owned Subsidiary

 Intimation of completion of US FDA inspection at Unit II of Eugia Pharma Specialities Limited, a wholly owned subsidiary of the Company.
Bigul
03 May 2024

AUROBINDO PHARMA LTD. - 524804 - Intimation Under Regulation 30 Of SEBI Listing Regulations. Ref: 1. Our Letter Dated May 2, 2024 Informing About The Receipt Of Orders From Statutory / Regulatory Authorities Reversing ITC And Imposing Interest And Penalty. 2. Your Email Dated May 3, 2024 Seeking All The Details Under SEBI Circular

 Submission of all the required details as per SEBI Circular dated July, 13, 2023 with regard to our disclosure submitted on May 2, 2024 informing about the receipt of order from statutory / regulatory authorities, the disclosure of which was submitted on May 2, 2024.
Bigul
02 May 2024

AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Acquisition

 Intimation of purchase of shares in Purple Bellflower Pty Limited, south Africa, a joint venture company and to make it a wholly owned subsidiary
Bigul
02 May 2024

AUROBINDO PHARMA LTD. - 524804 - The Company Has Received An Order From The Deputy Commissioner, Punjagutta Division, Hyderabad Passed Under Relevant Provisions Of The Central Goods And Services Tax Act, 2017 And TGST Act 2017 For The FY 2018-19 Demanding Reversal Of ITC

 The Company has received an order from Deputy Commission, Punjagutta, Hyderabad, Telangana demanding reversal of ITC.
Bigul
02 May 2024

AUROBINDO PHARMA LTD. - 524804 - Completion Of Disposal Of Business Assets Of Eugia US Manufacturing LLC

 Intimation about completion of disposal of business assets of Eugia US Manufacturing LLC, a wholly owned step-down subsidiary company
Bigul
23 Apr 2024

AUROBINDO PHARMA LTD. - 524804 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Intimation of issue of LoCs.
Bigul
22 Apr 2024

AUROBINDO PHARMA LTD. - 524804 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Intimation of loss of share certificate
Bigul
08 Apr 2024

AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Intimation of Investor meet.
See all News

FAQs

The latest market price of Aurobindo Pharma Ltd. on NSE was Rs. 1115.30 as of today.

The opening share price of Aurobindo Pharma Ltd. was Rs. 1136.00 as of today.

The 52-week high share price of Aurobindo Pharma Ltd. was Rs. 1177.10.

The 52 week low share price of Aurobindo Pharma Ltd. was Rs. 581.20.

Aurobindo Pharma Ltd. has a market cap of Rs. 65349.70 crore as of today. Please refer to the Fundamentals section for further details.

The PE ratio of Aurobindo Pharma Ltd. is 0.60. Please refer to the Fundamentals section for further details.

The operating revenue for Aurobindo Pharma Ltd. in the last FY was Rs.  27894.68 crore. Please refer to the Financials section for further details.

The Net Profit for Aurobindo Pharma Ltd. in the last FY was Rs. 2770.49 crore. Please refer to the Financials section for further details.

Please refer to Stock Ants, Bigul’s Community Access platform that aggregates tips and research from experts and provides real-time tracking to help investors validate, discover new investment ideas, and make informed decisions. Click here to learn more.

Please refer to Stock Ants, Bigul’s Community Access platform that aggregates tips and research from experts and provides real-time tracking to help investors validate, discover new investment ideas, and make informed decisions. Click here to learn more.

The latest dividend declared by Aurobindo Pharma Ltd. was on 2024-02-20 for Rs. 1.5 per share. According to today’s share price, the dividend yield of Aurobindo Pharma Ltd. stands at 0.40. Please refer to the Corporate Actions section for further details.

The latest bonus issue declared by Aurobindo Pharma Ltd. was as of 2015-07-20. The bonus ratio declared in this issue was 1:1. Please refer to the Corporate Actions section for further details.

The latest split issue declared by Aurobindo Pharma Ltd. was as of 2003-10-23. The split ratio declared in this issue was 10:5. Please refer to the Corporate Actions section for further details.

Please refer to Bigul Traders Corner, One Stop destination for different algo and non-algo trading strategies and tools meant for investors, traders, and strategists. Our qualified experts with rich experience in broking, financial analysis, and software development designed it in-house. Click here to learn more.

Please refer to JARVIS, which is Bigul’s AI Portfolio Manager Tool that uses artificial intelligence algorithms to make investment decisions in a portfolio. Click here to learn more.

Please refer to the News section for the latest news about Aurobindo Pharma Ltd..

Close

Let's Open Free Demat Account